Syngene International gets ₹8.62 Cr refund for AY 2014-15
Syngene International secured a ₹8.62 Cr refund for Assessment Year 2014-15 following an NFAC order. The refund reduces contingent liability, though the amount is yet to be credited.

*this image is generated using AI for illustrative purposes only.
Syngene International has secured a refund of ₹8.62 Cr for Assessment Year 2014-15 after tax authorities gave effect to an order passed by the National Faceless Appeal Centre (NFAC). The order, dated May 14, 2026, was received by the company on July 6, 2026, and concludes a litigation process that began with an initial demand of ₹16.72 Cr in 2016. While the refund amount is yet to be credited, the development will lead to a decrease in the company's contingent liability related to the financial period in question.
The dispute originated when the Deputy Commissioner of Income-tax, Circle 6(1)(1), Bangalore, passed an order under Section 143(3) of the Income Tax Act on December 23, 2016. This order disallowed certain deductions claimed by Syngene International and raised a demand of ₹16,72,20,900. Following an appeal filed by the company on January 24, 2017, the Assessing Officer passed a subsequent order under Section 154 of the Act on March 8, 2017, increasing the total demand to ₹33,69,27,800.
The NFAC intervened with an order under Section 250 of the Act dated February 13, 2026, partly allowing the company's appeal. The recent order from the Assessing Officer implements this NFAC decision, formally granting a refund of ₹8,62,14,600, which includes interest. Syngene International stated that it is currently analysing the order to determine if any further action is required.
Financial Implications
Syngene International stated that the order does not expect to have a material impact on its financials, operations, or activities. The primary accounting effect will be a reduction in the contingent liability associated with the Assessment Year 2014-15. No penalties, restrictions, or sanctions were imposed in the order.
Litigation Timeline
| Date | Event |
|---|---|
| December 23, 2016 | Initial order passed under Section 143(3) raising demand of ₹16,72,20,900 |
| January 24, 2017 | Company filed appeal against the disallowance |
| March 8, 2017 | Assessing Officer passed order under Section 154 increasing demand to ₹33,69,27,800 |
| February 13, 2026 | NFAC passed order under Section 250 partly allowing the appeal |
| May 14, 2026 | Order passed giving effect to NFAC order granting refund of ₹8,62,14,600 |
| July 6, 2026 | Communication received via SMS and downloaded from income tax website |
Historical Stock Returns for Syngene International
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.21% | -2.51% | -8.53% | -33.43% | -33.01% | -28.16% |
Will the successful resolution of this decade-long tax dispute encourage Syngene to pursue similar appeals for other pending litigations?
How will the reduction in contingent liabilities impact Syngene's credit ratings and borrowing costs in the near future?
Does the NFAC's decision set a favorable precedent for other pharmaceutical companies facing similar tax disallowances?































